{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:56:39Z","timestamp":1776941799826,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11864-019-0683-9","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T06:02:52Z","timestamp":1574748172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma"],"prefix":"10.1007","volume":"20","author":[{"given":"Erica","family":"Leavitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Lask","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"683_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/978-3-319-66884-0_47","volume-title":"Biologic and systemic agents in dermatology","author":"P Armstrong","year":"2018","unstructured":"Armstrong P, Martin S, Lask G. Sonic hedgehog pathway inhibition in the treatment of advanced basal cell carcinoma. In: Yamauchi P, editor. Biologic and systemic agents in dermatology. Berlin: Springer; 2018. p. 541\u20138."},{"issue":"3\u20134","key":"683_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1023\/B:CANC.0000031775.04618.30","volume":"23","author":"HW Walling","year":"2004","unstructured":"Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004;23(3\u20134):389\u2013402.","journal-title":"Cancer Metastasis Rev"},{"issue":"1\u20133","key":"683_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S1011-1344(01)00198-1","volume":"63","author":"BK Armstrong","year":"2001","unstructured":"Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63(1\u20133):8\u201318.","journal-title":"J Photochem Photobiol B"},{"issue":"3","key":"683_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nrm2636","volume":"10","author":"C Blanpain","year":"2009","unstructured":"Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol. 2009;10(3):207\u201317.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"683_CR5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/01.GIM.0000144188.15902.C4","volume":"6","author":"RJ Gorlin","year":"2004","unstructured":"Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004;6(6):530\u20139.","journal-title":"Genet Med"},{"issue":"18","key":"683_CR6","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1158\/0008-5472.CAN-14-1666","volume":"74","author":"M Athar","year":"2014","unstructured":"Athar M, Li C, Kim AL, Spiegelman VS, Bickers DR. Sonic hedgehog signaling in basal cell nevus syndrome. Cancer Res. 2014;74(18):4967\u201375.","journal-title":"Cancer Res"},{"key":"683_CR7","doi-asserted-by":"crossref","unstructured":"de Zwaan SE, Haass NK. Genetics of basal cell carcinoma. Australas J Dermatol. 2010;51(2):81\u201392 quiz 3-4.","DOI":"10.1111\/j.1440-0960.2009.00579.x"},{"issue":"5","key":"683_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/0190-9622(91)70108-E","volume":"24","author":"Jacob S. Lo","year":"1991","unstructured":"Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24(5 Pt 1):715\u20139.","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"683_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0190-9622(84)80334-5","volume":"10","author":"H von Domarus","year":"1984","unstructured":"von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984;10(6):1043\u201360.","journal-title":"J Am Acad Dermatol"},{"key":"683_CR10","unstructured":"Prescribing information: ERIVEDGE (vismodegib) capsule for oral use 2015 [Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2Available from: 015\/203388s005s006s007s008lbl.pdf."},{"issue":"23","key":"683_CR11","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A Sekulic","year":"2012","unstructured":"Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"683_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12885-019-5568-6","volume":"19","author":"A Sekulic","year":"2019","unstructured":"Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2019;19(1):366.","journal-title":"BMC Cancer"},{"issue":"3","key":"683_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","volume":"18","author":"Brigitte Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no B, Kunstfeld R, Hauschild A, Fosko S, Zloty D, Labeille B, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404\u201312 Study investigating intermittent vismodegib dosing regimens for BCC reduction in patients with multiple BCCs including NBCC syndrome.","journal-title":"The Lancet Oncology"},{"issue":"1","key":"683_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","volume":"70","author":"AL Chang","year":"2014","unstructured":"Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"683_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N. Basset-S\u00e9guin","year":"2017","unstructured":"Basset-S\u00e9guin N, Hauschild A, Kunstfeld R, Grob J, Dr\u00e9no B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334\u201348 Largest trial of over 1000 patients with advanced BCC treated with vismodegib.","journal-title":"European Journal of Cancer"},{"key":"683_CR16","unstructured":"ODOMZO (sonidegib) capsules, for oral use 2015 [Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205266s000lbl.pdf."},{"issue":"6","key":"683_CR17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","volume":"16","author":"MR Migden","year":"2015","unstructured":"Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716\u201328.","journal-title":"Lancet Oncol"},{"issue":"1","key":"683_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaad.2016.02.1226","volume":"75","author":"R Dummer","year":"2016","unstructured":"Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016;75(1):113\u201325.e5.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"683_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/jdv.14542","volume":"32","author":"J.T. Lear","year":"2017","unstructured":"Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372\u201381 Final update from the largest trial treating patients with sonidegib for advanced BCC.","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"683_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jaad.2018.07.004","volume":"79","author":"P Xie","year":"2018","unstructured":"Xie P, Lefran\u00e7ois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(6):1089\u2013100.e17.","journal-title":"J Am Acad Dermatol"},{"key":"683_CR21","doi-asserted-by":"crossref","unstructured":"Vogt M, Sethi A, Brocato J, Squittieri N. Notes and comments on efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: a systematic review and analysis. J Am Acad Dermatol. 2019.","DOI":"10.1016\/j.jaad.2019.03.094"},{"issue":"5","key":"683_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","volume":"152","author":"SV Mohan","year":"2016","unstructured":"Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang AL. Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma. JAMA Dermatol. 2016;152(5):527\u201332.","journal-title":"JAMA Dermatol."},{"issue":"4","key":"683_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaad.2017.03.038","volume":"77","author":"T Bhutani","year":"2017","unstructured":"Bhutani T, Abrouk M, Sima CS, Sadetsky N, Hou J, Caro I, et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017;77(4):713\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"683_CR24","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","volume":"21","author":"Mario E. Lacouture","year":"2016","unstructured":"Lacouture ME, Dr\u00e9no B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218\u201329 Review and proposed management algorithm of adverse evenets from Shh inhibitors.","journal-title":"The Oncologist"},{"issue":"4","key":"683_CR25","first-page":"277","volume":"13","author":"Sonja Grunewald","year":"2015","unstructured":"Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges. 2015;13(4):277\u201389 quiz 90.","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"23","key":"683_CR26","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","volume":"366","author":"JY Tang","year":"2012","unstructured":"Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"683_CR27","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/S1470-2045(16)30566-6","volume":"17","author":"JY Tang","year":"2016","unstructured":"Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1720\u201331.","journal-title":"Lancet Oncol."},{"issue":"8","key":"683_CR28","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/jid.2011.48","volume":"131","author":"H Skvara","year":"2011","unstructured":"Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131(8):1735\u201344.","journal-title":"J Invest Dermatol"},{"key":"683_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijpharm.2019.05.002","volume":"565","author":"MN Calienni","year":"2019","unstructured":"Calienni MN, Febres-Molina C, Llovera RE, Zevallos-Delgado C, Tuttolomondo ME, Paolino D, et al. Nanoformulation for potential topical delivery of vismodegib in skin cancer treatment. Int J Pharm. 2019;565:108\u201322.","journal-title":"Int J Pharm"},{"issue":"1","key":"683_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/lsm.23013","volume":"51","author":"UH Olesen","year":"2019","unstructured":"Olesen UH, Clergeaud G, Lerche CM, Andresen TL, Haedersdal M. Topical delivery of vismodegib using ablative fractional laser and micro-emulsion formulation in vitro. Lasers Surg Med. 2019;51(1):79\u201387.","journal-title":"Lasers Surg Med"},{"issue":"5","key":"683_CR31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","volume":"71","author":"MS Ally","year":"2014","unstructured":"Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):904\u201311.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"683_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/IOP.0000000000001166","volume":"35","author":"AR Gonz\u00e1lez","year":"2019","unstructured":"Gonz\u00e1lez AR, Etchichury D, Gil ME, Del Aguila R. Neoadjuvant vismodegib and Mohs micrographic surgery for locally advanced periocular basal cell carcinoma. Ophthalmic Plast Reconstr Surg. 2019;35(1):56\u201361.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"15","key":"683_CR33","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.1200\/JCO.2018.36.15_suppl.9509","volume":"36","author":"L Mortier","year":"2018","unstructured":"Mortier L, Bertrand N, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multi center, open-label, phase 2 trial (VISMONEO study). J Clin Oncol. 2018;36(15):9509.","journal-title":"J Clin Oncol"},{"issue":"3","key":"683_CR34","first-page":"219","volume":"14","author":"J Alcalay","year":"2015","unstructured":"Alcalay J, Tauber G, Fenig E, Hodak E. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma. J Drugs Dermatol. 2015;14(3):219\u201323.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"683_CR35","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/archdermatol.2012.2354","volume":"148","author":"AL Chang","year":"2012","unstructured":"Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324\u20135.","journal-title":"Arch Dermatol"},{"issue":"12","key":"683_CR36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1056\/NEJMoa0902903","volume":"361","author":"CM Rudin","year":"2009","unstructured":"Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12):1173\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"683_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.molonc.2014.09.003","volume":"9","author":"S Pricl","year":"2015","unstructured":"Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9(2):389\u201397.","journal-title":"Mol Oncol"},{"issue":"51","key":"683_CR38","doi-asserted-by":"publisher","first-page":"51ra70","DOI":"10.1126\/scitranslmed.3001599","volume":"2","author":"S Buonamici","year":"2010","unstructured":"Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010;2(51):51ra70.","journal-title":"Sci Transl Med"},{"issue":"7727","key":"683_CR39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-018-0596-y","volume":"562","author":"B Biehs","year":"2018","unstructured":"Biehs B, Dijkgraaf GJP, Piskol R, Alicke B, Boumahdi S, Peale F, et al. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. Nature. 2018;562(7727):429\u201333.","journal-title":"Nature."},{"key":"683_CR40","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jid.2018.11.035","volume":"139","author":"F Kuonen","year":"2019","unstructured":"Kuonen F, Huskey NE, Shankar G, Jaju P, Whitson RJ, Rieger KE, et al. Loss of primary cilia drives switching from Hedgehog to Ras\/MAPK pathway in resistant basal cell carcinoma. J Invest Dermatol. 2019;139:1439\u201348.","journal-title":"J Invest Dermatol."},{"issue":"4","key":"683_CR41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","volume":"17","author":"J Kim","year":"2010","unstructured":"Kim J, Tang JY, Gong R, Lee JJ, Clemons KV, Chong CR, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388\u201399.","journal-title":"Cancer Cell"},{"issue":"1","key":"683_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2012.11.017","volume":"23","author":"J Kim","year":"2013","unstructured":"Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23(1):23\u201334.","journal-title":"Cancer Cell"},{"issue":"8","key":"683_CR43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","volume":"32","author":"DJ Kim","year":"2014","unstructured":"Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745\u201351.","journal-title":"J Clin Oncol"},{"issue":"4","key":"683_CR44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/jamadermatol.2015.5473","volume":"152","author":"MS Ally","year":"2016","unstructured":"Ally MS, Ransohoff K, Sarin K, Atwood SX, Rezaee M, Bailey-Healy I, et al. Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma. JAMA Dermatol. 2016;152(4):452\u20136.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"683_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/cells8020153","volume":"8","author":"Daniel Girardi","year":"2019","unstructured":"Girardi D, Barrichello A, Fernandes G, Pereira A. Targeting the Hedgehog pathway in cancer: current evidence and future perspectives. Cells. 2019;8(2).","journal-title":"Cells"},{"issue":"5","key":"683_CR46","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/1535-7163.MCT-15-0729-T","volume":"15","author":"B Chen","year":"2016","unstructured":"Chen B, Trang V, Lee A, Williams NS, Wilson AN, Epstein EH, et al. Posaconazole, a second-generation triazole antifungal drug, inhibits the Hedgehog signaling pathway and progression of basal cell carcinoma. Mol Cancer Ther. 2016;15(5):866\u201376.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"683_CR47","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/sj.leu.2403021","volume":"17","author":"A List","year":"2003","unstructured":"List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld CS, et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia. 2003;17(8):1499\u2013507.","journal-title":"Leukemia."},{"issue":"1","key":"683_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1172\/JCI42874","volume":"121","author":"EM Beauchamp","year":"2011","unstructured":"Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog\/GLI pathway. J Clin Invest. 2011;121(1):148\u201360.","journal-title":"J Clin Invest"},{"issue":"30","key":"683_CR49","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.1006822107","volume":"107","author":"J Kim","year":"2010","unstructured":"Kim J, Lee JJ, Gardner D, Beachy PA. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010;107(30):13432\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"683_CR50","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.1073\/pnas.0609699104","volume":"104","author":"M Lauth","year":"2007","unstructured":"Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007;104(20):8455\u201360.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-019-0683-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T01:06:08Z","timestamp":1606266368000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-019-0683-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s11864-019-0683-9","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"26 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"84"}}